ID   CUTO-28 ROS1 p.G2032R
AC   CVCL_E6J7
RX   DOI=10.63028/10067/2105480151162165141;
CC   Characteristics: The ROS1 mutation introduced is most prevalent among patients presenting relapsed disease. Shows resistance to ceritinib, crizotinib, entrectinib and lorlatinib (DOI=10.63028/10067/2105480151162165141).
CC   Sequence variation: Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:12012; TPM3; Name(s)=TPM3-ROS1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:10261; ROS1; Simple_edited; p.Gly2032Arg (c.6094G>A) (p.Gly2026Arg, c.6076G>A); ClinVar=VCV000376139; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (DOI=10.63028/10067/2105480151162165141).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C8T2 ! CUTO-28
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   DOI=10.63028/10067/2105480151162165141;
RA   Terrones M.;
RT   "Profiling targeted therapy responses in ROS1+ non-small cell lung
RT   cancer using genomically engineered patient-derived cell lines.";
RL   Thesis PhD (2024); University of Antwerp; Antwerp; Belgium.
//